PubMed Health⌕ Search

PubMed · 8225397

CD45 isoform transitions on multinegative human thymocytes differentiating in vitro mimic patterns predicted for selective events in vivo.

Abstract

Experiments were designed to test the idea that the patterns of CD45 isoform expressed by differentiating human multinegative (MN) thymocytes (CD3- 4- 8- 19-) are regulated by the type of growth or activation stimuli delivered. We have proposed that within the thymus, CD45RA expression is fundamental to maintenance of the thymic generative lineage while a transition to CD45RO indicates entry into the path of intrathymic death. It seems likely that the signal transduction pathways leading to positive selection are different from those leading to negative selection. Upon culture, MN thymocytes proliferate in response to interleukin-2 (IL-2) or anti-CD2/28 and differentiate as defined by acquisition of CD3 as well as CD4 and/or CD8. Even at day 9 of culture, 30-40% of cells remain multinegative. DNA analysis indicates that both CD3- and CD3+ cells are actively cycling. Although the CD3- set includes a substantial number of cycling cells, it continues to express almost exclusively the CD45RA isoform. Among CD3+ progeny, 53-80% have acquired CD45RO while maintaining high expression of CD45RA, although 10-47% are able to maintain exclusive expression of CD45RA despite their more differentiated state. In contrast, stimulation with PHA/PMA, which gives a vigorous proliferative response, appears to inhibit acquisition of CD3 and thus differentiation, while forcing a premature transition from CD45RA to CD45RO. These in vitro systems appear to permit generative thymic development while maintaining a cycling multinegative subset, thus mimicking thymic development in vivo, permitting an exploration of the events in positive and negative selection of human thymocytes. The maintenance of CD45RA expression with co-expression of CD45RO by CD3+ progeny in cultures supplemented with IL-2 or anti-CD2/28, in contrast to the loss of CD45RA after PHA stimulation, shows that the regulation of CD45 isoform expression is closely linked to the nature of the developmental signals received by a thymocyte.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L M Pilarski, J P Deans. 1993. CD45 isoform transitions on multinegative human thymocytes differentiating in vitro mimic patterns predicted for selective events in vivo.. https://doi.org/10.1038/icb.1993.34

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ZrO₂@C-based colorimetric/photothermal dual-mode immunosensor coupled with a novel monoclonal antibody for quantification of Aspergillus ochraceus biomass.

Aspergillus ochraceus contaminates agricultural products and produces nephrotoxic, carcinogenic ochratoxin A (OTA), posing severe food safety hazards. A dual-signal lateral flow immunochromatographic assay (dLFIA) based on ZrO₂@C nanoprobes was established for quantitative detection of A. ochraceus biomass. A novel monoclonal antibody (mAb 4B4) was prepared as the capture antibody to immobilize A. ochraceus mycelial lysate antigen on the test line, and a rabbit polyclonal antibody (pAb G2801) as the detection antibody to modify ZrO₂@C composites (synthesized via UiO-66 pyrolysis) into 200 nm colorimetric/photothermal nanoprobes. This dLFIA achieved limits of detection of 0.164 μg/mL (colorimetric) and 0.517 μg/mL (photothermal). This efficient and reliable method allows quantitative analysis of A. ochraceus biomass, which is suitable for routine monitoring of fungal contamination in agro-food matrices.

Antibodies, Monoclonal↗

Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.

Lymphoproliferative disease (LPD) is a complication of congenital and acquired immunodeficiency states. There are a number of treatment options for LPD arising after haematopoietic stem cell or solid organ transplantation including reduction of immunosuppression, targeted therapies, such as the anti-CD20 monoclonal antibody, rituximab, and EBV specific cytotoxic lymphocytes. Treatment of LPD in children with congenital immunodeficiency syndromes remains unsatisfactory and is associated with a high mortality rate. We recently managed an infant found to have polymorphic LPD concurrent with X-linked severe combined immunodeficiency (SCID). Haematopoietic stem cell transplantation (HSCT) had to be deferred because of progressive LPD. Treatment with rituximab resulted in regression of the LPD following which the patient received a 5/6 HLA matched umbilical cord blood (UCB) transplant. The patient remains well 20 months following transplantation. Rituximab treatment may have a useful role in the control of LPD associated with congenital immunodeficiency prior to HSCT.

Antibodies, Monoclonal↗

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab.

Antibodies, Monoclonal↗